Analyst firms · Piper Sandler · VRTX

Piper Sandler VRTX price target and rating history

Vertex Pharmaceuticals Incorporated (VRTX) · Health Care

Piper Sandler rates Vertex Pharmaceuticals Incorporated (VRTX) Overweight with a $385 price target, as of its latest action on May 4, 2023. It has published 3 rating actions on VRTX since July 2021, including 0 upgrades and 1 downgrade. Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50.

Current rating
Overweight
Price target
$385
Median target, all firms
$577.50
Actions on VRTX
3

Piper Sandler price target on VRTX

$385$302$21820222023202420252026
Piper Sandler price target on VRTX, each point a stated target, July 2021 to May 2023.

Every Piper Sandler rating on VRTX

How other firms rate VRTX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Leerink PartnersOutperform$594Sep 21, 2026
Morgan StanleyOverweight$665Sep 2, 2026
Truist SecuritiesBuy$542May 27, 2026
Maxim GroupBuy$575Mar 18, 2026
JefferiesBuy$580Mar 10, 2026
OppenheimerOutperform$600Mar 10, 2026
BarclaysOverweight$606Jan 28, 2026
RBC Capital MarketsOutperform$546Jan 22, 2026
BernsteinOutperformJan 12, 2026
UBSBuy$535Jan 7, 2026
Wolfe ResearchOutperform$548Jan 6, 2026

Questions about Piper Sandler and VRTX

What is Piper Sandler's price target for VRTX?
Piper Sandler's latest stated price target for Vertex Pharmaceuticals Incorporated (VRTX) is $385, from its action on May 4, 2023.
What is Piper Sandler's rating on VRTX?
Piper Sandler rates VRTX Overweight, a bullish rating, as of May 4, 2023.
When did Piper Sandler last change its view on VRTX?
On May 4, 2023, Piper Sandler resumes coverage at Overweight, price target $385.
How does Piper Sandler's VRTX target compare with other analysts?
Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50.

More VRTX rating histories

All Piper Sandler ratingsVRTX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.